A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
a study on Solid Tumor Neoplasms
- for people ages 12 years and up (full criteria)
- at Orange, California and other locations
- study startedestimated completion
- Principal Investigator
- by Misako Nagasaka, M.D.
Locally Advanced Solid Tumors, Metastatic Solid Tumors, ALK, ROS1, NTRK, Sarcoma, Lung Neoplasms, Carcinoma, NSCL, NSCLC, Non Small Cell Lung, Thyroid Disease, Colonic Neoplasms, Thyroid Neoplasms, Carcinoma, Neuroendocrine, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Disease, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Endocrine System Disease, Colorectol Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Gastrointestinal Disease, Colonic Disease, Intestinal Disease, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Neuroendocrine Tumors, Neuroectodermal Tumors, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Adenocarcinoma, Non Small Cell Lung Cancer, Solid Tumors, Rearrangements, TRIDENT-1, TKI, TKI naive, TKI pretreated, Anti-tumor activity, Repotrectinib, Advanced Solid Malignancies, Oral repotrectinib (TPX-0005), Repotrectinib (TPX-0005)
Lead Scientist at UC Irvine
- Misako Nagasaka, M.D.
Associate Clinical Professor, Medicine, School of Medicine. Authored (or co-authored) 123 research publications
- accepting new patients
- Start Date
- Completion Date
- Turning Point Therapeutics, Inc.
- Phase 1/2 research study
- Study Type
- Expecting 500 study participants
- Last Updated